This stock looks like RIMM earlier in the year (pre-split). ISRG refuses to dip below its 50-day SMA and has come nowhere near its 100-day SMA since March. Such is the way for a company with great, life-saving technology.
ISRG is now closer to 400 than it is to 200, which is right about where its 200-day SMA is (201). If ISRG makes a move to 402, I expect to see major unloading from fund managers.
What I had to do was to find stocks that would be hoisted up because they stirred people's imagination for the future. ... I was not interested in the company's individual products, whether it was metals for rockets, solid fuel, or advanced electronic equipment. In fact, I did not want to know what they made—that information might only inhibit me. I did not care what the company's products were, any more than I was influenced by the fact that the board chairman had a beautiful wife. But I did want to know whether the company belonged to a new vigorous infant industry and whether it be haved in the market according to my requirements.
This, of course, was directly against the advice of many financial writers with conservative backgrounds who have been pounding into investors for generations that they must study company reports and balance sheets, find out all they can about a stock's background, in order to make a wise investment. I decided that was not for me. All a company report and balance sheet can tell you is the past and the present. They cannot tell the future. And it was for this I had to project my plans.
No comments:
Post a Comment